Prognostic factors of nasopharyngeal cancer：An examination of 45 cases in Kyushu University Hospital

DOI
  • TARUTANI Yu
    Department of Otorhinolaryngology-Head and Neck Surgery, Kyushu University Hospital
  • MATSUO Mioko
    Department of Otorhinolaryngology-Head and Neck Surgery, Kyushu University Hospital
  • HASHIMOTO Kazuki
    Department of Otorhinolaryngology-Head and Neck Surgery, Kyushu University Hospital
  • KOGO Ryunosuke
    Department of Otorhinolaryngology-Head and Neck Surgery, Kyushu University Hospital
  • JIROMARU Rina
    Department of Otorhinolaryngology-Head and Neck Surgery, Kyushu University Hospital
  • HONGO Takahiro
    Department of Otorhinolaryngology-Head and Neck Surgery, Kyushu University Hospital
  • MANAKO Tomomi
    Department of Otorhinolaryngology-Head and Neck Surgery, Kyushu University Hospital
  • NAKAGAWA Takashi
    Department of Otorhinolaryngology-Head and Neck Surgery, Kyushu University Hospital

Bibliographic Information

Other Title
  • 当科における上咽頭癌の予後因子についての検討

Search this article

Description

<p>In 2018, the new TNM classification (AJCC 8th edition) was introduced. We investigated the prognosis of nasopharyngeal cancer in 45 nasopharyngeal cancer patients who underwent first-line therapy at the Department of Otolaryngology, Head and Neck Surgery, Kyushu University between January 2010 and January 2020. There were 31 male and 14 female patients, ranging in age from 12 to 88 years old, with a median age of 59 years old. Of these, 40 patients with nasopharyngeal squamous cell carcinoma were evaluated for their five-year overall survival (OS) and progression-free survival (PFS) as well as prognostic factors. The 5-year OS rate was 75.5%, and the 5-year PFS rate was 64.3%. As prognostic factors, there were no significant differences in outcome by stage, histological type, and Epstein-Barr virus positivity. In addition, it was considered necessary to further investigate the optimal dose of cisplatin for chemoradiotherapy combined with cisplatin, which is the main treatment for nasopharyngeal cancer.</p>

Journal

  • jibi to rinsho

    jibi to rinsho 69 (2), 75-81, 2023-03-20

    JIBI TO RINSHO KAI

Keywords

Details 詳細情報について

Report a problem

Back to top